Solventum SOLV R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Solventum in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Solventum’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solventum's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solventum's R&D?
- Solventum (SOLV) reported R&D of $189M in Q1 2026.
- How has Solventum's R&D changed year-over-year?
- Solventum's R&D decreased by 2.1% year-over-year, from $193M to $189M.
- What is the long-term trend for Solventum's R&D?
- Over 3 years (2022 to 2025), Solventum's R&D has grown at a -1.2% compound annual growth rate (CAGR), from $767M to $740M.
- What does R&D mean?
- The money spent on innovation and developing new products or services.
- How do you interpret R&D?
- Higher spending signals a commitment to long-term growth and innovation, whereas significant cuts may suggest a focus on short-term profitability over future viability.
- How does R&D compare across companies?
- Highly comparable among healthcare and technology peers; usually expressed as a percentage of revenue.